<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Psychiatry</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Psychiatry</journal-id>
      <journal-title-group>
        <journal-title>BMC Psychiatry</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-244X</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26911800</article-id>
      <article-id pub-id-type="pmc">4765112</article-id>
      <article-id pub-id-type="publisher-id">754</article-id>
      <article-id pub-id-type="doi">10.1186/s12888-016-0754-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Intravenous melatonin abuse leading to recurrent aortic valve endocarditis: a case report and discussion</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Warren</surname>
            <given-names>Mark B.</given-names>
          </name>
          <address>
            <email>mark.warren@va.gov</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stabler</surname>
            <given-names>Jonathan</given-names>
          </name>
          <address>
            <email>jonathan.stabler@va.gov</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hagman</surname>
            <given-names>Melissa M.</given-names>
          </name>
          <address>
            <email>Melissa.hagman2@va.gov</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Psychiatry, University of Washington, Boise Veterans Administration Medical Center, 500 W. Fort St., Boise, ID 83702 USA </aff>
        <aff id="Aff2"><label/>Department of Internal Medicine, University of Washington, Boise Veterans Administration Medical Center, 500 W. Fort St., Boise, ID 83702 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>2</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>24</day>
        <month>2</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>16</volume>
      <elocation-id>39</elocation-id>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>10</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>2</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Warren et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Reports of inappropriate medication use are widespread. There is a growing literature detailing abuse of drugs not typically thought to have high abuse liability. Melatonin is considered to be generally safe and is categorized by the Food and Drug Administration as a nutritional supplement. There are no known reports of intravenous melatonin abuse in the medical literature.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>The authors report a case of a patient injecting melatonin with euphoric and then sedative effects leading to two episodes of infective endocarditis culminating in aortic valve replacement.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Infective endocarditis continues to be a major potential complication of intravenous drug abuse. The proliferation of novel street drugs, resurgence in the use of older drugs and ongoing abuse of medications warrant continued research and vigilance in treating substance use disorders and attendant medical complications.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Infective endocarditis</kwd>
        <kwd>Melatonin abuse</kwd>
        <kwd>Melatonin injection</kwd>
        <kwd>
          <italic>Granulicatella adiacens</italic>
        </kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>The changing landscape of drug use, including continued innovation of street drugs [<xref ref-type="bibr" rid="CR1">1</xref>], intravenous injection of tablets meant for oral ingestion [<xref ref-type="bibr" rid="CR2">2</xref>] and a changing demographic and resurgence in abuse of older drugs such as heroin [<xref ref-type="bibr" rid="CR3">3</xref>], present a continuing challenge to healthcare teams. Prescription opioid and benzodiazepine abuse is a widely known problem but there is a growing literature describing abuse of medications that are not conventionally considered to have high abuse liability including several types of antidepressants [<xref ref-type="bibr" rid="CR4">4</xref>]. Intravenous injection of tablets can lead to complications such as infective endocarditis (IE), stroke and a variety of pulmonary pathology [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p>We report a case of a patient injecting melatonin tablets leading to IE initially with <italic>Granulicatella adiacens</italic> and subsequently with <italic>Streptococcus salivarius</italic> (<italic>viridans</italic>) necessitating aortic valve replacement. Melatonin is thought to be generally safe and is categorized by the FDA as a dietary supplement. It is a neurohormone produced by the pineal gland and thought to be important in the maintenance of the sleep-wake cycle. It is most commonly used for general sleep disorders, jet lag and other circadian rhythm disorders and has also been reported to have cytostatic action on some human cancers at doses typically between 1.5&#xA0;mg and 10&#xA0;mg at night with variable efficacy. Common side effects include fatigue, somnolence and hypothermia. There are no known absolute contraindications to its use but caution is advised with hepatic or renal impairment or immune disorders [<xref ref-type="bibr" rid="CR6">6</xref>]. It has not been reported to have high abuse liablity, nor reported to cause euphoria. To our knowledge this is the first report of its kind in the literature.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>Mr. S is a 58-year-old gentleman with a complicated medical history including recurrent pulmonary embolism related to antiphospholipid syndrome (APS), pulmonary arteriovenous malformation, major depression with two prior deliberate overdose attempts and remote intravenous drug abuse (IVDA). He initially presented to a community hospital following a motor vehicle accident after new onset seizures and was found to have a small intraparenchymal brain hemorrhage. Anticoagulation was held and he recovered with no long-term neurologic sequelae.</p>
      <p>One month later he was admitted to inpatient medicine with suicidal ideation and hyponatremia, stabilized and transferred to psychiatry. Later exam revealed a weight increase of 2.3 kg over a 48&#xA0;h period along with low grade fever, new systolic and diastolic murmurs, significant bilateral lower extremity edema and recurrence of hyponatremia. Blood cultures grew <italic>Granulicatella adiacens</italic> and trans-esophageal echocardiogram showed aortic valve vegetations and moderate to severe regurgitation. He was treated for endocarditis with penicillin and gentamicin. The infection was attributed to poor dentition (Mr. S adamantly denied any IVDA) and three teeth were extracted. He was referred for valve replacement but this was postponed due to concern over bleeding risk.</p>
      <p>Over the next several months, Mr. S. had multiple admissions to inpatient psychiatry for suicidality and a medical admission for pulmonary embolism and worsening biventricular heart failure. He was referred again for valve replacement.</p>
      <p>Prior to surgery he presented with increasing malaise, fevers and chills. Blood cultures grew <italic>Streptococcus salivarius</italic> (<italic>viridans</italic>) and examination showed worsening heart failure, mitral and aortic insufficiency murmurs, splinter hemorrhages on two fingers and a Janeway lesion on the left distal forearm. Additionally, he had a palpable venous cord with overlying injection marks on the right lateral wrist. Echocardiogram showed aortic valve endocarditis with mobile vegetation (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) and severe regurgitation. He was treated with targeted intravenous antibiotics.<fig id="Fig1"><label>Fig. 1</label><caption><p>Echocardiogram showing mobile aortic valve vegetation</p></caption><graphic xlink:href="12888_2016_754_Fig1_HTML" id="MO1"/></fig></p>
      <p>During this admission Mr. S reported he had been crushing single 5&#xA0;mg tablets of melatonin, mixing with ice water and injecting intravenously several times per week, up to two times per day for the past two years. He confirmed this history on psychiatric consultation and added that he now had a sense of relief about having &#x201C;a clean slate, no more secrets.&#x201D; Mr. S. described an initial euphoric effect with melatonin injection. This diminished but he continued injecting to help initiate sleep.</p>
      <p>Mr. S underwent aortic valve replacement a week after he disclosed to staff his abuse of melatonin. Of note, he had only one psychiatric hospitalization in the nine months subsequent to his valve replacement compared with six inpatient psychiatric admissions in the year prior to his surgery.</p>
    </sec>
    <sec id="Sec3">
      <title>Discussion</title>
      <p>Melatonin is thought to be generally safe with no reported abuse liability and its prescription drug counterpart, ramelteon, a melatonin receptor agonist, is also thought to have low to no abuse potential [<xref ref-type="bibr" rid="CR7">7</xref>]. Intravenous injection of any substance, however, places individuals at risk for infectious and embolic complications and continues to be a source of worldwide medical and public health attention [<xref ref-type="bibr" rid="CR8">8</xref>]. Mr. S&#x2019;s complications from melatonin injection included recurrent aortic valve endocarditis and we hypothesize that his initial stroke may have been due to tablet material traveling through his known pulmonary arteriovenous malformation. These types of embolic phenomena have been reported with injection of other types of tablets [<xref ref-type="bibr" rid="CR9">9</xref>]. It must be noted that his recurrent endocarditis was most likely related to injection habits and nonsterile technique as opposed to any melatonin-specific characteristics.</p>
      <p>IE remains a serious illness with high morbidity and mortality [<xref ref-type="bibr" rid="CR10">10</xref>]. Its approximate incidence is 3 to 9 cases per 100,000 in industrialized nations. The precise incidence of IE in IVDA is not known but remains problematic [<xref ref-type="bibr" rid="CR8">8</xref>]. It is estimated that up to 41&#xA0;% of IVDA patients with bacteremia will develop IE [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
      <p>Offending organisms in IE are most often streptococci and staphylococci [<xref ref-type="bibr" rid="CR12">12</xref>]. IE caused by <italic>Granulicatella adiacens</italic> is thought to be a rare but increasingly frequent cause and can be associated with severe cases of bacteremia regardless of prior immune state. A case series and literature review from early 2015 identified only 29 published cases of IE due to <italic>G. adiacens</italic> and infection carried a 17% mortality rate. Forty-four percent of cases involved the aortic valve [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
    </sec>
    <sec id="Sec4">
      <title>Conclusions</title>
      <p>We report the first known case of recreational melatonin injection leading to IE with <italic>Granulicatella adiacens</italic> and subsequently with <italic>Streptococcus salivarius</italic> (<italic>viridans</italic>) necessitating aortic valve replacement. IE continues as a major potential complication of IVDA. The proliferation of novel street drugs, resurgence in the use of older street drugs and ongoing abuse of prescribed medications and dietary supplements warrant continual research and vigilance in treating substance use disorders and attendant medical complications.</p>
      <sec id="Sec5">
        <title>Consent</title>
        <p>Written consent for publication in the medical literature to include pertinent imaging was obtained from the patient.</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>IE</term>
          <def>
            <p>Infective endocarditis</p>
          </def>
        </def-item>
        <def-item>
          <term>IVDA</term>
          <def>
            <p>Intravenous drug abuse</p>
          </def>
        </def-item>
        <def-item>
          <term>APS</term>
          <def>
            <p>Antiphospholipid syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>FDA</term>
          <def>
            <p>Food and Drug Administration</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>MBW, MMH and JS were all involved in the care and treatment of the patient and participated in the preparation of, read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nelson</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Bryant</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Aks</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>Emerging drugs of abuse</article-title>
          <source>Dis Mon</source>
          <year>2014</year>
          <volume>60</volume>
          <issue>3</issue>
          <fpage>110</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="doi">10.1016/j.disamonth.2014.01.001</pub-id>
          <pub-id pub-id-type="pmid">24629403</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Young</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Havens</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Leukefeld</surname>
              <given-names>CG</given-names>
            </name>
          </person-group>
          <article-title>Route of administration for illicit prescription opioids: a comparison of rural and urban drug users</article-title>
          <source>Harm Reduct J</source>
          <year>2010</year>
          <volume>7</volume>
          <fpage>24</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1186/1477-7517-7-24</pub-id>
          <pub-id pub-id-type="pmid">20950455</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cicero</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Surratt</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Kurtz</surname>
              <given-names>SP</given-names>
            </name>
          </person-group>
          <article-title>The changing face of heroin use in the United States: a retrospective analysis of the past 50&#xA0;years</article-title>
          <source>JAMA Psychiatry</source>
          <year>2014</year>
          <volume>71</volume>
          <issue>7</issue>
          <fpage>821</fpage>
          <lpage>826</lpage>
          <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.366</pub-id>
          <pub-id pub-id-type="pmid">24871348</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Abuse and misuse of antidepressants</article-title>
          <source>Subst Abuse Rehabil</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>107</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">25187753</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nguyen</surname>
              <given-names>VT</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>SH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pulmonary effects of i.v. injection of crushed oral tablets: &#x201C;excipient lung disease.&#x201D;</article-title>
          <source>Am J Roentgenol</source>
          <year>2014</year>
          <volume>203</volume>
          <issue>5</issue>
          <fpage>W506</fpage>
          <lpage>515</lpage>
          <pub-id pub-id-type="doi">10.2214/AJR.14.12582</pub-id>
          <pub-id pub-id-type="pmid">25341165</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Omar</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Saba</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Melatonin, receptors, mechanism, and uses</article-title>
          <source>Syst Rev Pharm</source>
          <year>2010</year>
          <volume>1</volume>
          <issue>2</issue>
          <fpage>158</fpage>
          <lpage>171</lpage>
          <pub-id pub-id-type="doi">10.4103/0975-8453.75069</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Griffiths</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Relative abuse potential of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds</article-title>
          <source>J Clin Psychiatr</source>
          <year>2005</year>
          <volume>66</volume>
          <issue>suppl 9</issue>
          <fpage>31</fpage>
          <lpage>41</lpage>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sousa</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Botelho</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Azeredo</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Infective endocarditis in intravenous drug abusers: an update</article-title>
          <source>Eur J Microbiol Infect Dis</source>
          <year>2012</year>
          <volume>31</volume>
          <issue>11</issue>
          <fpage>2905</fpage>
          <lpage>2910</lpage>
          <pub-id pub-id-type="doi">10.1007/s10096-012-1675-x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lim</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Hui</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Embolic stroke associated with injection of buprenorphine tablets</article-title>
          <source>Neurology</source>
          <year>2009</year>
          <volume>73</volume>
          <issue>11</issue>
          <fpage>876</fpage>
          <lpage>879</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181b784c0</pub-id>
          <pub-id pub-id-type="pmid">19752455</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="other">Slipczuk L, Codolosa N, Davila C, et al. Infective endocarditis epidemiology over five decades: a systematic review. PLoS One. 2013;8(12):e82665:1&#x2013;17.</mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Starakis</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mazokopakis</surname>
              <given-names>EE</given-names>
            </name>
          </person-group>
          <article-title>Injecting illicit substances epidemic and infective endocarditis</article-title>
          <source>Infectious Disorders-Drug Targets</source>
          <year>2010</year>
          <volume>10</volume>
          <issue>1</issue>
          <fpage>22</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.2174/187152610790410891</pub-id>
          <pub-id pub-id-type="pmid">20218949</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Duval</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Infective Endocarditis</article-title>
          <source>New Engl J Med</source>
          <year>2013</year>
          <volume>368</volume>
          <issue>15</issue>
          <fpage>1425</fpage>
          <lpage>1433</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMcp1206782</pub-id>
          <pub-id pub-id-type="pmid">23574121</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adam</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Siciliano</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Gualandro</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Case series of infective endocarditis caused by <italic>Granulicatella species</italic></article-title>
          <source>Int J Infect Dis</source>
          <year>2015</year>
          <volume>31</volume>
          <fpage>56</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijid.2014.10.023</pub-id>
          <pub-id pub-id-type="pmid">25461651</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
